tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Prescott TA et al. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor. 2014 FEBS Lett. pmid:24374339
Kamburova EG et al. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. 2014 PLoS ONE pmid:25393622
Filler G and Smith N The need for tacrolimus assay standardization. 2014 Ther Drug Monit pmid:25390282
Jun H et al. Experiences on conversion to once-daily Advagraf and sirolimus combination in stable kidney recipients. 2014 Transplant. Proc. pmid:24655973
Sachewsky N et al. Cyclosporin A enhances neural precursor cell survival in mice through a calcineurin-independent pathway. 2014 Dis Model Mech pmid:25056698
Masutani K et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. 2014 Transplant. Proc. pmid:24655972
Erdinest N and Solomon A Topical immunomodulators in the management of allergic eye diseases. 2014 Curr Opin Allergy Clin Immunol pmid:25054831
Mo D et al. In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei. 2014 Mycopathologia pmid:25052248
Tian SY et al. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. 2014 J. Rheumatol. pmid:25225281
Klawitter J et al. Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism. 2014 PLoS ONE pmid:24497939
Mori T et al. Nephrotoxicity of concomitant use of tacrolimus and teicoplanin in allogeneic hematopoietic stem cell transplant recipients. 2014 Transpl Infect Dis pmid:24494811
Alloway RR et al. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. 2014 Liver Transpl. pmid:24493215
DU C et al. [In vitro effects of tacrolimus on platelet function]. 2014 Zhonghua Xue Ye Xue Za Zhi pmid:25339327
Hartmann A et al. Treatment of generalised vitiligo with tacrolimus 0.1% ointment vs. UVB intense pulsed light phototherapy: a pilot study. 2014 Acta Derm. Venereol. pmid:24473666
Yin Z et al. Topical pimecrolimus inhibits high-dose UVB irradiation-induced epidermal Langerhans cell migration, via regulation of TNF-α and E-cadherin. 2014 Drug Des Devel Ther pmid:25336924
Tsuchimoto A et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. 2014 PLoS ONE pmid:25329716
Qi H et al. The antiaging activity and cerebral protection of rapamycin at micro-doses. 2014 CNS Neurosci Ther pmid:25327787
El-Sheikh AA et al. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. 2014 Transl Res pmid:24486136
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Xie M et al. Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience. 2014 Pediatr Transplant pmid:24283660
Balato A et al. Tacrolimus does not alter the production of several cytokines and antimicrobial peptide in Malassezia furfur-infected-keratinocytes. 2014 Mycoses pmid:24512536
Qin XL et al. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. 2014 Drug Metab. Dispos. pmid:24195812
Li CJ et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. 2014 PLoS ONE pmid:24465960
Silva-Cunha A et al. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. 2014 J Ocul Pharmacol Ther pmid:24199740
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Chen D et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. 2014 Drug Metab. Pharmacokinet. pmid:24351870
Bruel A et al. Early protocol biopsies in pediatric renal transplantation: interest for the adaptation of immunosuppression. 2014 Pediatr Transplant pmid:24341571
Sapir-Pichhadze R et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. 2014 Kidney Int. pmid:24336032
Danby SG et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. 2014 Br. J. Dermatol. pmid:24328907
Kato H et al. Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. 2014 Bone Marrow Transplant. pmid:24317130
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Cho A et al. Calcineurin signaling regulates neural induction through antagonizing the BMP pathway. 2014 Neuron pmid:24698271
Teraki Y [Atopic dermatitis in pregnancy]. 2014 Arerugi pmid:24714179
Casey MJ et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. 2014 Transplantation pmid:24717218
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Hirai F et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. 2014 J. Gastroenterol. Hepatol. pmid:24033383
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Shlivko IL et al. Morphological changes in skin of different phototypes under the action of topical corticosteroid therapy and tacrolimus. 2014 Skin Res Technol pmid:23808907
Jalil MH et al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. 2014 Br J Clin Pharmacol pmid:23738951
Deng Z et al. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation]. 2014 Zhonghua Er Ke Za Zhi pmid:25224233
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Posadas Salas MA and Srinivas TR Update on the clinical utility of once-daily tacrolimus in the management of transplantation. 2014 Drug Des Devel Ther pmid:25210441
Tanaka H et al. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. 2014 Lupus pmid:24651669
Taber DJ et al. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. 2014 Am. J. Nephrol. pmid:24969370
Jacobo-Cabral CO et al. Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. 2014 Pediatr Transplant pmid:25156476
Keniya MV et al. Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. 2014 Mol. Pharm. pmid:25115303
Shah NP et al. Treatment of a Crohn's disease-related cutaneous facial lesion with topical tacrolimus. 2014 Oral Surg Oral Med Oral Pathol Oral Radiol pmid:25151593
Werk AN et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. 2014 Clin. Pharmacol. Ther. pmid:24126681
Chatterjea A et al. Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats. 2014 J. Cell. Mol. Med. pmid:24237965
Størset E et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. 2014 Br J Clin Pharmacol pmid:25279405
Pichler R et al. De novo renal cell carcinoma in a kidney allograft with focus on contrast-enhanced ultrasound. 2014 Urol. Int. pmid:25115614
Ko SF et al. Therapeutic potential of tacrolimus on acute myocardial infarction in minipigs: analysis with serial cardiac magnetic resonance and changes at histological and protein levels. 2014 Biomed Res Int pmid:25114905
Zivčić-Ćosić S et al. Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period. 2014 Int Urol Nephrol pmid:23515930
Hadjipanagi D et al. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population. 2014 BMC Res Notes pmid:24593903
Yan YH et al. Role of FK506 binding protein 12 in morphine-induced μ-opioid receptor internalization and desensitization. 2014 Neurosci. Lett. pmid:24607931
Bogan JS Endocytic cycling of glucose transporters and insulin resistance due to immunosuppressive agents. 2014 J. Clin. Endocrinol. Metab. pmid:25279573
Sethna CB and Gipson DS Treatment of FSGS in Children. 2014 Adv Chronic Kidney Dis pmid:24602468
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Demmers MW et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. 2014 Transplantation pmid:24157471
Tsuchida T et al. The development of humanized liver with Rag1 knockout rats. 2014 Transplant. Proc. pmid:24815157
Kraus TS et al. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient. 2014 Acta Haematol. pmid:24157860
Hostettler KE et al. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 Eur. Respir. J. pmid:23645405
Oda K and Yamano K Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506). 2014 Biopharm Drug Dispos pmid:25059890
Lapteva M et al. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. 2014 Mol. Pharm. pmid:25057896
Oh CK et al. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation. 2014 Yonsei Med. J. pmid:25048494
Levinger E et al. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. 2014 Graefes Arch. Clin. Exp. Ophthalmol. pmid:24696044
GoriaÄ­nov VA et al. [Effect of tacrolimus on the results of living related kidney donor transplantation]. 2014 Ter. Arkh. pmid:25095659
Shilpa PS et al. Topical tacrolimus in the management of oral lichen planus: literature review. 2014 J Calif Dent Assoc pmid:25080722
Carbajal R et al. Case report: boldo (Peumus boldus) and tacrolimus interaction in a renal transplant patient. 2014 Transplant. Proc. pmid:24981811
Kuramitsu S et al. [Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy]. 2014 Fukuoka Igaku Zasshi pmid:25000660
Kluk J et al. Follicular mucinosis treated with topical 0.1% tacrolimus ointment. 2014 Clin. Exp. Dermatol. pmid:24252117
Ohe M et al. Successful treatment with tacrolimus of refractory adult-onset Still's disease. 2014 Korean J. Intern. Med. pmid:24648814
Kassir N et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. 2014 Br J Clin Pharmacol pmid:24977292
Matsumoto K et al. [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report]. 2014 Hinyokika Kiyo pmid:25001642
Friedrich RB et al. Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations. 2014 J Biomed Nanotechnol pmid:25016659
Wu Q et al. Heterogeneity of radiological spectrum in tacrolimus-associated encephalopathy after lung transplantation. 2014 Behav Neurol pmid:24970980
Toniutto P et al. Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated. 2014 Int J Surg pmid:25219480
Buechter M et al. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4-associated cholangitis. 2014 Z Gastroenterol pmid:24905108
Wohlfahrtova M and Viklicky O Recent trials in immunosuppression and their consequences for current therapy. 2014 Curr Opin Organ Transplant pmid:24905020
Boonyapredee M et al. Increased BK viremia and progression to BK-virus nephropathy following high-dose intravenous immunoglobulin for acute cellular rejection. 2014 Mil Med pmid:24902140
Langone A et al. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation. 2014 Clin Transplant pmid:24893821
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Lebel MJ et al. Increase in de novo food allergies after pediatric liver transplantation: tacrolimus vs. cyclosporine immunosuppression. 2014 Pediatr Transplant pmid:25156571
Kurbalija V et al. Time-series analysis in the medical domain: a study of Tacrolimus administration and influence on kidney graft function. 2014 Comput. Biol. Med. pmid:24813681
Reitamo S and Remitz A An update on current pharmacotherapy options in atopic dermatitis. 2014 Expert Opin Pharmacother pmid:24811606
Stifft F et al. Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. 2014 Br J Clin Pharmacol pmid:24809233
Korbel L et al. Clinically relevant pharmacogenomic testing in pediatric practice. 2014 Clin Pediatr (Phila) pmid:24803633
Kallash M and Aviles D Efficacy of tacrolimus in the treatment of children with focal segmental glomerulosclerosis. 2014 World J Pediatr pmid:24801235
Yamanaka M et al. Development and evaluation of a tacrolimus cream formulation using a binary solvent system. 2014 Int J Pharm pmid:24456671
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Dipchand AI et al. Myocyte growth, repair, and oxidative stress following pediatric heart transplantation. 2014 Pediatr Transplant pmid:25118092
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Hošková L et al. Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system. 2014 Hypertens. Res. pmid:24718302
Lee SJ et al. Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants. 2014 Sci Rep pmid:25491116
Miller EC et al. Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits. 2014 Eur. J. Neurosci. pmid:24713000
Fernandes MB et al. Supplementation with omega-3 polyunsaturated fatty acids and experimental tacrolimus-induced nephrotoxicity. 2014 Exp Clin Transplant pmid:25489802
Supe-Markovina K et al. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience. 2014 Pediatr Transplant pmid:24712738
Chung BH et al. Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. 2014 Transpl. Immunol. pmid:24709525
Al-Kadhimi Z et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. 2014 Biol. Blood Marrow Transplant. pmid:24709007
Larkins N and Matsell DG Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomes. 2014 Pediatr Transplant pmid:25284168